Table 1.
Comparison of clinical and pathologic features by VA of survivin expression for 310 patients with ccRCC
| Feature | Survivin-positive tumor cells/mm2 | P value | |
|---|---|---|---|
| <15 Low expression n = 205 |
≥15 High expression n = 105 |
||
| n (%) | |||
| Age at surgery (y) | |||
| <65 | 109 (53.2) | 46 (43.8) | .119 |
| ≥65 | 96 (46.8) | 59 (56.2) | |
| Sex | |||
| Female | 78 (38.0) | 47 (44.8) | .254 |
| Male | 127 (62.0) | 58 (55.2) | |
| Symptoms at presentation | |||
| No | 77 (37.6) | 28 (26.7) | .055 |
| Yes | 128 (62.4) | 77 (73.3) | |
| Constitutional symptoms at presentation | |||
| No | 161 (78.5) | 64 (61.0) | .001 |
| Yes | 44 (21.5) | 41 (39.0) | |
| ECOG performance status | |||
| 0 | 183 (89.3) | 97 (92.4) | .380 |
| ≥1 | 22 (10.7) | 8 (7.6) | |
| Tumor thrombus | |||
| None | 173 (84.4) | 66 (62.9) | <.001 |
| Level 0 | 20 (9.8) | 23 (21.9) | |
| Level I-IV | 12 (5.8) | 16 (15.2) | |
| Type of surgery | |||
| Nephron-sparing surgery | 31 (15.1) | 11 (10.5) | .258 |
| Radical nephrectomy | 174 (84.9) | 94 (89.5) | |
| Primary tumor size(cm) | |||
| <5 | 95 (46.3) | 28 (26.7) | .002 |
| 5 to <7 | 46 (22.4) | 22 (21.0) | |
| 7 to <10 | 31 (15.1) | 27 (25.7) | |
| ≥10 | 33 (16.1) | 28 (26.7) | |
| 2002 Primary tumor classification | |||
| pT1a | 77 (37.6) | 19 (18.1) | <.001 |
| pT1b | 65 (31.7) | 29 (27.6) | |
| pT2 | 19 (9.3) | 9 (8.6) | |
| pT3a | 11 (5.4) | 9 (8.6) | |
| pT3b | 27 (13.2) | 36 (34.3) | |
| pT3c | 4 (2.0) | 2 (1.9) | |
| pT4 | 2 (1.0) | 1 (1.0) | |
| Perinephric fat invasion | |||
| No | 175 (85.4) | 75 (71.4) | .003 |
| Yes | 30 (14.6) | 30 (28.6) | |
| Regional lymph node involvement | |||
| pNX and pN0 | 200 (97.6) | 96 (91.4) | .020 |
| pN1 and pN2 | 5 (2.4) | 9 (8.6) | |
| Distant metastases | |||
| pM0 | 193 (94.2) | 88 (83.8) | .003 |
| pM1 | 12 (5.8) | 17 (16.2) | |
| 2002 TNM stage groupings | |||
| I | 137 (66.8) | 46 (43.8) | <.001 |
| II | 18 (8.8) | 3 (2.9) | |
| III | 35 (17.1) | 36 (34.3) | |
| Nuclear grade | |||
| 1 | 34 (16.6) | 3 (2.9) | <.001 |
| 2 | 114 (55.6) | 32 (30.5) | |
| 3 | 52 (25.4) | 43 (41.0) | |
| 4 | 5 (2.4) | 27 (25.7) | |
| Coagulative tumor necrosis | |||
| No | 174 (84.9) | 43 (41.0) | <.001 |
| Yes | 31 (15.1) | 62 (59.0) | |
| Sarcomatoid differentiation | |||
| No | 202 (98.5) | 90 (85.7) | <.001 |
| Yes | 3 (1.5) | 15 (14.3) | |